Meeting
2016 ASCO Annual Meeting
Genetic landscape of ALK+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1.
Authors
Daniel Shao-Weng Tan
National Cancer Centre, Singapore, Singapore
Daniel Shao-Weng Tan , Dong-Wan Kim , Michael Thomas , Serafino Pantano , Ying Wang , Sebastian Lukasz Szpakowski , Alejandro Javier Yovine , Ranee Mehra , Laura Q. Chow , Sunil Sharma , Benjamin J. Solomon , Enriqueta Felip , D. Ross Camidge , Johan F. Vansteenkiste , Hans Bitter , Lilli M. Petruzzelli , Margaret Han Dugan , Alice T. Shaw
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
TBC
Citation
J Clin Oncol 34, 2016 (suppl; abstr 9064)
DOI
10.1200/JCO.2016.34.15_suppl.9064
Abstract #
9064
Poster Bd #
387
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Longitudinal monitoring by next generation sequencing of plasma cell-free DNA in ALK-rearranged non-small cell lung cancer (NSCLC) patients treated with ALK tyrosine kinase inhibitors.
First Author: Minsuk Kwon
Poster
2020 ASCO Virtual Scientific Program
Anaplastic lymphoma kinase (ALK) partners identified by next-generation sequencing in Chinese patients with solid tumors.
First Author: Sheng Yang
Poster
2020 ASCO Virtual Scientific Program
Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.
First Author: D. Ross Camidge
Poster
2014 ASCO Annual Meeting
Identifying ALK rearrangements that are not detected by FISH with targeted next-generation sequencing of lung carcinoma.
First Author: Siraj M. Ali